Lv4
488 积分 2021-11-19 加入
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer
12天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
1个月前
已完结
A Roadmap to Precision Immunotherapy for Early-Stage Non–Small Cell Lung Cancer
1个月前
已完结
Antitumour immunity regulated by aberrant ERBB family signalling
2个月前
已完结
Clonal driver neoantigen loss under EGFR TKI and immune selection pressures
2个月前
已完结
The biology and functional importance of MAIT cells
4个月前
已完结
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLC
4个月前
已完结
Osimertinib in Stage III EGFR -Mutated NSCLC — Game, Set, Match
8个月前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
8个月前
已完结
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
8个月前
已完结
皖公网安备34019202002308
